Is Cefdinir a Strong Antibiotic? How It Compares

Cefdinir is a moderately potent oral antibiotic, not one of the heavy hitters reserved for serious or drug-resistant infections, but stronger than many first-line options for common community-acquired illnesses. It belongs to the third generation of cephalosporins, a family related to penicillin, and it covers a broader range of bacteria than older oral antibiotics in its class. Where cefdinir lands on the “strength” spectrum depends on what infection you’re comparing it for, which is why a blanket label of strong or weak misses the point.

What “Strong” Actually Means for an Antibiotic

People tend to think of antibiotics on a linear scale from weak to strong, like pain medications. That framing doesn’t map well onto how antibiotics work. An antibiotic’s potency depends on the specific bacterium it’s targeting, because each drug kills or inhibits certain species at certain concentrations and does nothing to others. The lab measurement that captures this is the minimum concentration of the drug needed to stop a particular bacterial strain from growing. A drug that requires only a tiny concentration to halt a pathogen is “strong” against that pathogen, while the same drug might be useless against a different one.

So when your doctor prescribes cefdinir, the question isn’t really whether it’s strong in the abstract. It’s whether it reliably kills the bacteria most likely causing your infection at the doses you can take by mouth. For the infections it’s approved for, the answer is generally yes.

What Cefdinir Is Designed to Treat

Cefdinir is approved for a specific set of mild-to-moderate community-acquired infections: community-acquired pneumonia, flare-ups of chronic bronchitis, acute sinus infections, strep throat and tonsillitis, ear infections, and uncomplicated skin infections in both adults and children.¹ That’s a wide list, but notice the recurring word: community-acquired. Cefdinir is built for the kinds of infections you pick up in daily life, not the stubborn hospital-bred bacteria that tend to resist multiple drugs.

Its strength lies in covering the three bacteria that cause most respiratory infections. Against Haemophilus influenzae, one of the leading culprits behind sinusitis and bronchitis flare-ups, cefdinir showed susceptibility rates above 97% in surveillance testing.² It also covers Moraxella catarrhalis well, another common respiratory pathogen. Against Streptococcus pneumoniae, the picture is good but not perfect, with susceptibility rates in the high 70s to low 80s percent range depending on the year tested.²

One reason cefdinir holds up well against these pathogens is that it resists breakdown by beta-lactamases, enzymes that many bacteria produce to destroy penicillin-family drugs. Some strains of H. influenzae and M. catarrhalis churn out these enzymes, which is why plain amoxicillin sometimes fails. Cefdinir stays intact.³ It is also one of the few oral third-generation cephalosporins with meaningful activity against common Gram-positive bacteria, including staph.⁴

How Cefdinir Compares to Amoxicillin-Clavulanate

Amoxicillin-clavulanate (commonly known by the brand name Augmentin) is probably the most frequent head-to-head comparison for cefdinir, since both are prescribed for many of the same infections. The short version: for most infections, they perform similarly, with some important exceptions.

For acute sinusitis, clinical trials found cefdinir and amoxicillin-clavulanate achieved roughly the same cure rates, around 90%, with cefdinir having the added convenience of once-daily dosing versus three times daily for the comparator.⁵ Additional trials confirmed this equivalence in sinus infections, showing cefdinir matched both amoxicillin-clavulanate and levofloxacin (a fluoroquinolone) for acute bacterial rhinosinusitis.⁶

Ear infections in children, however, reveal a split. In one trial comparing standard-dose cefdinir to amoxicillin-clavulanate in kids with suppurative acute otitis media, overall clinical success rates were statistically equivalent: about 80-86% across treatment groups.⁷ But when researchers looked specifically at eradication of Streptococcus pneumoniae, cefdinir’s twice-daily regimen cleared the bacterium only about 55% of the time, compared to roughly 90% for amoxicillin-clavulanate.⁷ A separate trial using high-dose amoxicillin-clavulanate showed an even more pronounced gap, with cure rates of about 87% versus 71% for cefdinir, driven largely by children under two years old and those with recurrent ear infections.⁸

This is the pattern to remember: for garden-variety sinus and respiratory infections in adults, cefdinir and amoxicillin-clavulanate are essentially interchangeable. For pediatric ear infections, especially in very young children or those with recurrent episodes, high-dose amoxicillin-clavulanate tends to outperform cefdinir, particularly against pneumococcus.

The Tolerability Trade-Off

If amoxicillin-clavulanate has an edge in certain infections, why do doctors prescribe cefdinir at all? A big part of the answer is side effects and compliance. Amoxicillin-clavulanate is notorious for causing diarrhea, thanks to the clavulanate component. In one pediatric ear infection trial, diarrhea occurred in 35% of children on amoxicillin-clavulanate compared with 10-13% on cefdinir.⁷ Another study found that parents gave cefdinir significantly better marks for ease of use (89% versus 57%), taste (85% versus 39%), and treatment adherence (82% versus 61%).⁹

For children, these numbers matter enormously. An antibiotic that sits in the fridge because a child refuses to swallow it, or one that causes enough diarrhea that parents stop the course early, isn’t effective regardless of what the lab data say. Palatability studies have consistently ranked cefdinir’s oral suspension among the best-tasting options, preferred over amoxicillin-clavulanate, cefprozil, and azithromycin by children aged four to eight.¹⁰ When researchers factored in taste, cost, dosing frequency, and treatment duration, cefdinir ranked second overall behind azithromycin for pediatric compliance.¹¹

Cefdinir Versus Azithromycin

Azithromycin (the “Z-pack”) is the other antibiotic patients frequently ask about when comparing with cefdinir. Both are used for respiratory and ear infections, and both are considered convenient oral options. In a head-to-head trial for acute ear infections in children, five days of cefdinir and five days of azithromycin produced comparable cure rates: about 87% and 85%, respectively.¹²

Where the two drugs differ more meaningfully is in their spectrum and resistance profiles. Azithromycin is a macrolide, a completely different class from cephalosporins. Macrolide resistance among Streptococcus pneumoniae has been climbing in many regions, which has made cefdinir a useful alternative in areas where macrolide resistance is common.¹³ On the flip side, azithromycin covers atypical organisms like Mycoplasma pneumoniae that cefdinir does not touch. So the choice between the two often comes down to what your doctor suspects is causing the infection and what resistance patterns look like locally.

How Cefdinir Stacks Up Against Other Cephalosporins

Within its own family, cefdinir is a third-generation cephalosporin, which broadly means it trades some of the Gram-positive coverage of older generations for better Gram-negative reach. Compared to the first-generation drug cephalexin (Keflex), cefdinir covers more respiratory pathogens but may not be a clear upgrade for every infection type. A retrospective study comparing the two for urinary tract infections found treatment failure rates at 14 days of about 21% for cefdinir versus 12% for cephalexin, though the difference was not statistically significant.¹⁴ That result surprised some clinicians, since a “higher generation” drug might be expected to do better. But urinary tract infections are predominantly caused by E. coli and other Gram-negative organisms that cephalexin handles well, and the broader spectrum of cefdinir doesn’t necessarily translate to better outcomes for that particular infection.

Against other oral cephalosporins used for respiratory infections, trials have shown cefdinir’s clinical and bacteriological efficacy to be equivalent to cefprozil, cefuroxime axetil, cefaclor, and loracarbef for pneumonia and bronchitis.¹⁵ In a trial specifically comparing cefdinir and cefaclor for community-acquired pneumonia, satisfactory clinical response rates were 89% and 86%, respectively.¹⁶ The practical advantages of cefdinir over some of these older cephalosporins include better beta-lactamase stability and a dosing schedule that allows once-daily administration.³

Where Cefdinir Falls Short

Knowing what cefdinir can’t do is just as important as knowing what it can. It is not effective against bacteria producing extended-spectrum beta-lactamases (ESBLs), a class of resistance enzymes increasingly common in hospital settings. Lab testing has shown that ESBL-producing E. coli strains have enhanced resistance to cefdinir along with most other third-generation cephalosporins.¹⁷ While cefdinir shows good stability against the more common, simpler beta-lactamases, these extended-spectrum enzymes chew through it.¹⁸

Cefdinir also has no useful activity against MRSA (methicillin-resistant Staphylococcus aureus), Pseudomonas aeruginosa, or anaerobic bacteria. If your doctor suspects any of these, cefdinir is the wrong tool. And because it’s an oral drug with moderate bioavailability, it isn’t designed for severe infections that need high blood levels of antibiotic quickly. For serious pneumonia requiring hospitalization, bloodstream infections, or deep-seated abscesses, intravenous antibiotics are the standard.

The C. Diff Risk Worth Knowing About

All antibiotics carry some risk of disrupting gut flora enough to allow Clostridioides difficile, a toxin-producing bacterium, to take hold. But the risk is not equal across drugs. A large U.S. study covering 2008 to 2020 found that cefdinir was among the highest-risk antibiotics for community-acquired C. difficile infection. Compared to doxycycline (used as a low-risk reference), cefdinir carried roughly six times the risk, placing it second only to clindamycin and ahead of both cefuroxime and fluoroquinolones.¹⁹

That doesn’t mean everyone who takes cefdinir gets C. diff. The absolute risk is still low. One analysis estimated about 5.7 extra cases of C. difficile per 100,000 outpatient antibiotic prescriptions for upper respiratory infections.²⁰ But on a population level, when millions of prescriptions are written, those cases add up. This risk is a genuine reason why infectious-disease specialists have pushed back on reflexive cefdinir prescribing for infections that could be treated with narrower-spectrum drugs.

The Mysterious Red Stool

If you’re taking cefdinir and notice alarming red or rust-colored stool, don’t panic. This happens when cefdinir or one of its breakdown products binds to iron in the gut, forming a reddish complex that passes through. It’s particularly common in infants on iron-supplemented formulas.²¹ The discoloration is harmless and resolves once you stop the antibiotic, but it has sent more than a few parents to the emergency room fearing blood in their child’s diaper. Beyond the scare factor, the iron interaction can reduce how much cefdinir your body absorbs. Most prescribing guidance recommends separating cefdinir doses from iron supplements or iron-fortified products by at least two hours.

Dosing Convenience and Kidney Function

One of cefdinir’s practical selling points is flexibility. Adults and teenagers typically take 300 mg twice daily or 600 mg once daily for 5 to 10 days, depending on the infection. Children take a weight-based dose, usually around 14 mg/kg per day, split into one or two doses.¹³ The once-daily option is a real advantage for people who struggle with multi-dose regimens.

For people with significantly reduced kidney function, though, the drug clears much more slowly. Studies in hemodialysis patients found the elimination half-life stretched to roughly 17 hours, far longer than in people with healthy kidneys, meaning the drug accumulates unless doses are adjusted. Hemodialysis itself does remove cefdinir effectively, but the prolonged exposure between sessions means doctors need to reduce the dose or extend the dosing interval.²²

When Cefdinir Is a Good Choice and When It Isn’t

Cefdinir fills a real niche. It’s a reasonable pick for a sinus infection in an adult who can’t tolerate amoxicillin-clavulanate’s gastrointestinal effects. It’s a good option for strep throat in someone with a non-severe penicillin allergy (cephalosporins carry low cross-reactivity risk in that population). And it’s a sensible choice for pediatric ear infections in children who refuse other suspensions, because a completed course of a slightly less potent drug beats half a course of a theoretically better one that the child spits out.

Where it’s less ideal: urinary tract infections (narrower-spectrum drugs like cephalexin or nitrofurantoin are usually better matched), any infection involving MRSA or Pseudomonas, situations requiring high-dose pneumococcal coverage in very young children (high-dose amoxicillin-clavulanate tends to win there), and cases where avoiding C. difficile risk is a high priority, such as elderly patients or those with a history of C. diff. The drug remains an important option in the oral antibiotic toolkit, particularly in communities where beta-lactamase production or macrolide resistance limits other choices.¹³ But like any antibiotic, it works best when matched to the right bug and the right patient rather than prescribed as a default.